MX369911B - Método basado en expresión génica para clasificar pacientes con cãncer de riñón de acuerdo al riesgo de recurrencia. - Google Patents

Método basado en expresión génica para clasificar pacientes con cãncer de riñón de acuerdo al riesgo de recurrencia.

Info

Publication number
MX369911B
MX369911B MX2015012782A MX2015012782A MX369911B MX 369911 B MX369911 B MX 369911B MX 2015012782 A MX2015012782 A MX 2015012782A MX 2015012782 A MX2015012782 A MX 2015012782A MX 369911 B MX369911 B MX 369911B
Authority
MX
Mexico
Prior art keywords
kidney cancer
patient
calculating
gene expression
expression profile
Prior art date
Application number
MX2015012782A
Other languages
English (en)
Spanish (es)
Other versions
MX2015012782A (es
Inventor
Knezevic Dejan
Shak Steven
Andrew Watson George
R Crager Michael
Maddala Tara
Lopatin Margarita
Goddard Audrey
Svedman Christer
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of MX2015012782A publication Critical patent/MX2015012782A/es
Publication of MX369911B publication Critical patent/MX369911B/es

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C99/00Subject matter not provided for in other groups of this subclass
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16ZINFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00Subject matter not provided for in other main groups of this subclass
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Primary Health Care (AREA)
  • Computing Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2015012782A 2013-05-30 2014-05-29 Método basado en expresión génica para clasificar pacientes con cãncer de riñón de acuerdo al riesgo de recurrencia. MX369911B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361829100P 2013-05-30 2013-05-30
PCT/US2014/040003 WO2014194078A1 (en) 2013-05-30 2014-05-29 Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer

Publications (2)

Publication Number Publication Date
MX2015012782A MX2015012782A (es) 2016-02-05
MX369911B true MX369911B (es) 2019-11-26

Family

ID=51989393

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012782A MX369911B (es) 2013-05-30 2014-05-29 Método basado en expresión génica para clasificar pacientes con cãncer de riñón de acuerdo al riesgo de recurrencia.
MX2019013953A MX2019013953A (es) 2013-05-30 2015-09-14 Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019013953A MX2019013953A (es) 2013-05-30 2015-09-14 Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.

Country Status (11)

Country Link
US (3) US10181008B2 (cg-RX-API-DMAC7.html)
EP (2) EP3825420A1 (cg-RX-API-DMAC7.html)
JP (3) JP2016521979A (cg-RX-API-DMAC7.html)
AU (2) AU2014274135B2 (cg-RX-API-DMAC7.html)
CA (2) CA2903878C (cg-RX-API-DMAC7.html)
DK (1) DK3004392T3 (cg-RX-API-DMAC7.html)
ES (1) ES2829415T3 (cg-RX-API-DMAC7.html)
IL (2) IL240919B (cg-RX-API-DMAC7.html)
MX (2) MX369911B (cg-RX-API-DMAC7.html)
SG (2) SG11201506987VA (cg-RX-API-DMAC7.html)
WO (1) WO2014194078A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018187767A1 (en) * 2017-04-06 2018-10-11 The Regents Of The University Of California Predicting, diagnosing, and treating nausea and vomiting of pregnancy
WO2019075251A2 (en) * 2017-10-12 2019-04-18 Nantomics, Llc CANCER SCORE FOR EVALUATION AND PREDICTION OF RESPONSE FROM BIOLOGICAL FLUIDS
EP3874274B1 (en) 2018-10-31 2024-01-03 Regents of the University of Minnesota Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer
KR102280204B1 (ko) * 2018-12-13 2021-07-21 연세대학교 산학협력단 신장 세포 암의 종양의 병리학적 등급에 대한 정보를 제공하기 위한 방법 및 장치
CA3126455A1 (en) * 2019-01-11 2020-07-16 Quadrus Medical Technologies, Inc. Systems and methods for assessing and evaluating renal health diagnosis, staging, and therapy recommendation
EP3978629A1 (en) * 2020-10-01 2022-04-06 Koninklijke Philips N.V. Prediction of an outcome of a bladder or kidney cancer subject
CN113593640B (zh) * 2021-08-03 2023-07-28 哈尔滨市米杰生物科技有限公司 一种鳞癌组织功能状态与细胞组分评估方法及系统
WO2025085824A1 (en) * 2023-10-20 2025-04-24 Memorial Sloan-Kettering Cancer Center Multi-scale analysis of ribonucleic acid sequence data for predicting responses to anti-cancer therapies
CN117935910B (zh) * 2024-01-26 2024-09-17 华中农业大学 玉米snp位点的筛选方法、装置、电子设备及介质

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135314B1 (en) 1997-04-17 2006-11-14 Cell Therapeutics, Inc. Human phosphatidic acid phosphatase
WO2001051635A2 (en) 2000-01-13 2001-07-19 Genentech, Inc. Novel stra6 polypeptides
US6475855B1 (en) 2000-03-01 2002-11-05 Micron Technology, Inc. Method of forming integrated circuitry, method of forming a capacitor and method of forming DRAM integrated circuitry
DE10126344A1 (de) 2000-07-14 2002-01-24 Max Planck Gesellschaft Apoptose-induzierende DNA-Sequenzen
WO2002027028A1 (en) 2000-09-28 2002-04-04 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
US20030109434A1 (en) 2001-03-19 2003-06-12 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002079411A2 (en) * 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
JP2005500832A (ja) 2001-06-18 2005-01-13 ロゼッタ・インファーマティクス・インコーポレーテッド 乳癌患者の診断および予後
US7470509B2 (en) 2002-02-08 2008-12-30 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
DK1918386T3 (da) 2002-03-13 2012-01-02 Genomic Health Inc Genekspressionsprofiler i biopsier af tumorvæv
WO2004032842A2 (en) 2002-10-04 2004-04-22 Van Andel Research Institute Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
US7611839B2 (en) 2002-11-21 2009-11-03 Wyeth Methods for diagnosing RCC and other solid tumors
CA2523798A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
CA2530738C (en) 2003-06-24 2020-01-21 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
WO2005005661A2 (en) 2003-07-02 2005-01-20 Novartis Ag Genes regulated in ovarian cancer as prognostic and therapeutic targets
US20050002904A1 (en) 2003-07-03 2005-01-06 Wary Kishore K. Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
DK1644858T3 (da) * 2003-07-10 2018-01-22 Genomic Health Inc Funktionel beklædning med mindst et yderlag og en indermembran.
JP2005211023A (ja) 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
US20070224596A1 (en) 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
EP1737980A2 (en) * 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
CA2564850A1 (en) * 2004-05-04 2005-11-17 Bulent Soyupak Mn/ca ix/ ca9 and renal cancer prognosis
CN101023185A (zh) 2004-05-27 2007-08-22 威特克斯医药股份有限公司 用于监测impdh通路抑制作用的生物学标记
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
US20080119367A1 (en) 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
US20090258002A1 (en) 2005-02-01 2009-10-15 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for Tissue Status
US20090061423A1 (en) 2005-02-18 2009-03-05 Wyeth Pharmacogenomic markers for prognosis of solid tumors
WO2006124836A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
WO2006124022A1 (en) 2005-05-13 2006-11-23 Vanandel Research Institute Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma
US20070037186A1 (en) 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
EP1899486A4 (en) 2005-06-08 2009-07-22 Millennium Pharm Inc METHOD FOR IDENTIFYING, ASSESSING AND TREATING PATIENTS IN CANCER THERAPY
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP4312256B2 (ja) 2005-06-15 2009-08-12 ファイザー・リミテッド 寄生生物に対して使用する置換アリールピラゾール
EP1930426A4 (en) 2005-09-02 2009-04-29 Toray Industries COMPOSITION AND METHOD FOR DIAGNOSING KIDNEY CANCER AND ASSESSING THE PROGNOSIS OF A KIDNEY CANCER PATIENTS
US8343738B2 (en) 2005-09-14 2013-01-01 Human Genetic Signatures Pty. Ltd. Assay for screening for potential cervical cancer
EP2332984A3 (en) 2005-09-30 2011-10-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP1960551A2 (en) 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007111733A2 (en) 2005-12-16 2007-10-04 Genentech, Inc. Method for diagnosing, prognosing and treating glioma
US20080242606A1 (en) 2006-06-06 2008-10-02 Zhong Jiang Use of IMP3 as a Prognostic Marker for Cancer
MX2009001489A (es) 2006-08-10 2009-02-18 Millennium Pharm Inc Para la identificacion, valoracion y tratamiento de pacientes con terapia de cancer.
US8450057B2 (en) 2006-08-14 2013-05-28 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
US9034574B2 (en) * 2006-12-27 2015-05-19 The Johns Hopkins University Agents for reversing epigenetic silencing of genes
US20080286273A1 (en) 2007-05-02 2008-11-20 Siemens Medical Solutions Usa, Inc. Knowledge-Based Proliferation Signatures and Methods of Use
EP1990417A1 (en) 2007-05-11 2008-11-12 Universität Bayreuth Archaeal plasmid vector system
WO2009105640A1 (en) 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
CA2743473C (en) 2008-11-17 2022-06-14 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
AU2010264763B2 (en) 2009-06-26 2015-07-23 Noviogendix Research B.V. Molecular markers in kidney cancer
US9005891B2 (en) 2009-11-10 2015-04-14 Genomic Health, Inc. Methods for depleting RNA from nucleic acid samples
US20110123990A1 (en) * 2009-11-23 2011-05-26 Baker Joffre B Methods To Predict Clinical Outcome Of Cancer
WO2011085263A2 (en) * 2010-01-11 2011-07-14 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
WO2012174282A2 (en) * 2011-06-16 2012-12-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
CA2843756A1 (en) 2011-08-22 2013-02-28 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof

Also Published As

Publication number Publication date
AU2020204502A1 (en) 2020-07-23
NZ711680A (en) 2021-05-28
CA2903878C (en) 2020-10-27
US20190095575A1 (en) 2019-03-28
JP2018161151A (ja) 2018-10-18
IL283548A (en) 2021-07-29
MX2019013953A (es) 2020-01-30
EP3004392A1 (en) 2016-04-13
EP3004392A4 (en) 2017-01-25
HK1223132A1 (en) 2017-07-21
EP3825420A1 (en) 2021-05-26
AU2014274135A1 (en) 2015-09-24
SG10201709537PA (en) 2017-12-28
US20220044760A9 (en) 2022-02-10
CA3093128C (en) 2023-01-03
MX2015012782A (es) 2016-02-05
US10181008B2 (en) 2019-01-15
JP2020191896A (ja) 2020-12-03
JP2016521979A (ja) 2016-07-28
WO2014194078A1 (en) 2014-12-04
EP3004392B1 (en) 2020-09-30
US20210151122A1 (en) 2021-05-20
CA2903878A1 (en) 2014-12-04
IL240919B (en) 2021-06-30
SG11201506987VA (en) 2015-10-29
AU2014274135B2 (en) 2020-04-09
DK3004392T3 (da) 2020-10-26
IL240919A0 (en) 2015-10-29
US20160048632A1 (en) 2016-02-18
US11551782B2 (en) 2023-01-10
ES2829415T3 (es) 2021-05-31
NZ752676A (en) 2021-05-28
CA3093128A1 (en) 2014-12-04
AU2020204502B2 (en) 2022-02-17
JP7301798B2 (ja) 2023-07-03

Similar Documents

Publication Publication Date Title
MX2019013953A (es) Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.
MX2019007814A (es) Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
WO2014144121A3 (en) Classification and actionability indices for lung cancer
EP3800253A3 (en) Prostate cancer detection kit or device, and detection method
EP3967769A3 (en) Lung cancer detection kit or device, and detection method
EP3971299A3 (en) Colorectal cancer detection kit or device, and detection method
EP3816303A3 (en) Breast cancer detection kit or device, and method for detecting breast cancer
DK3080585T3 (da) Biosensorer til biologisk eller kemisk analyse og fremgangsmåder til fremstilling heraf
EP4495266A3 (en) Esophageal cancer detection kit or device, and detection method
AU362346S (en) Analyte meter
EP2619587A4 (en) BIOMARKER FOR PREDICTING THE REPRODUCTION OF A COLORECTAL CARCINOMA
EP3798316A3 (en) Genes and gene signatures for diagnosis and treatment of melanoma
EP4265740A3 (en) Methods for predicting risk of metastasis in cutaneous melanoma
EA201501137A1 (ru) Биомаркеры генной экспрессии и их использование для диагностического и прогностического применения у пациентов, потенциально нуждающихся в лечении ингибитором hdac
WO2015115923A3 (en) A profile of microrna in the blood as a test for the detection of lung cancer
EA202190962A2 (ru) Уровни экспрессии иммуноглобулинов в качестве биологического маркера для реакции на ингибитор протеасом
EA201690354A1 (ru) Уровни экспрессии иммуноглобулинов в качестве биологического маркера для реакции на ингибитор протеасом
WO2015148645A3 (en) Methods and kits for the prognosis and treatment of prostate cancer
WO2013190468A3 (en) Computer-based predictor for prostate cancer
GB201210864D0 (en) Treatment of cancer
WO2014009055A9 (en) Method and kit for predicting or monitoring the response of a cancer patient to chemotherapy, based on measuring the expression level of tmem45a gene.
RU2012144143A (ru) Способ определения чувствительности злокачественной опухоли к химиопрепарату
Kovalyuk IDIOMS, METAPHOR AND CULTURE
UA99752U (uk) Спосіб прогнозування гематологічної токсичності хіміотерапії у хворих на рак грудної залози
RU2013120609A (ru) Способ косвенного определения чувствительности клеток рака легкого к цисплатину на основании уровней экспрессии маркерных генов и набор для его осуществления

Legal Events

Date Code Title Description
FG Grant or registration